Lerapolturev
Phase 2Small molecule
Lerapolturev is one of 119 small molecule programs targeting Malignant Glioma. It is currently in Phase 2.
3
Indications
5
Total Trials
1
Active Trials
118
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Pegylated Interferon-Alpha-2a
AstraZenecaPhase 3
Relatlimab+nivolumab
Bristol-Myers SquibbPhase 3
Vusolimogene Oderparepvec
YYana Najjar
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Isolated Limb Perfusion
MMemorial Sloan Kettering Cancer Center
Phase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Brenetafusp
IImmunocore Ltd
Phase 3
PEG-Intron
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioblastoma1 trial
Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lerapolturev. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IIstari Oncology, Inc.